• Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me
  KJA Associates, LLC - part-time CFO services


Arrivo BioVentures, LLC

A
privately held, venture backed biopharmaceutical development company accelerating biologics and small molecules to improve patient care. Arrivo identifies IND ready/Phase I molecules and advances development through Phase IIb (proof of concept). Arrivo was launched in 2016 with $49M in committed capital.

Ms. Adams has been engaged by Arrivo to provide financial guidance, structure and support from inception through funding activities and asset acquisition.

 

Emergo Therapeutics, Inc.

Emergo Therapeutics is a privately held, clinical stage biopharmaceutical company developing off patent drugs and related compounds for the treatment of acute inflammatory conditions. 

Ms. Adams has been engaged by Emergo to provide financial guidance, operational structure and support as the Company prepares to raise its first funding round.


QuatroBio, LLC


QuatroBio is the management company for two early-stage drug development companies.

The first, Midnight Pharma LLC, is developing a novel product for the treatment of insomnia and is in Phase 2 and raised $7M in a series A investment. The second, Velo Bio LLC, is developing an orphan drug for the treatment of severe preeclampsia (DIF program) in pregnant women, also in Phase 2. AMAG Pharmaceuticals, Inc. paid $10M  for the option to acquire global rights to the DIF program.
​
QuatroBio was founded by the same management team which founded (and subsequently sold) Aerial BioPharma (JZP-110 asset sale), Neuronex, and Addrenex. All successful drug development companies in the RTP area of North Carolina which Ms. Adams was also associated with in the role of CFO beginning in 2007.

As one of the founders of the QuatroBio, Ms. Adams is continuing as CFO and is responsible for supporting business development and fund raising efforts as well as the internal accounting and financial reporting structure, yearly audits, risk management and human resources as the team advances the drug  development programs in Midnight and Velo.

Picture
Picture
Picture
Picture
Picture
Picture
©2023 Copyright Karen J. Adams, All Rights Reserved
Powered by Create your own unique website with customizable templates.
  • Home
  • Current Clients
  • Client List
  • Clients In the News
    • 2020 News Releases >
      • Aerial BioPharma JZP-110 Jan 2020
    • 2019 News Releases >
      • Emergo Therapeutics Aug 2019
      • Emergo Therapeutics May 2019
      • Emergo Therapeutics April 2019
      • Aerial BioPharma JZP-110 March 2019
    • 2018 News Releases >
      • Emergo Therapeutics 2018
    • 2017 News Releases >
      • Aerial BioPharma JZP-110 Dec
    • 2016 News Releases >
      • Target PharmaSolutions Nov
      • Target PharmaSolutions Oct
      • Arrivo BIoVentures
      • Contego Medical
    • 2015 News Releases >
      • Contego Medical
      • AMAG Pharmaceuticals Announces Further Expansion of Maternal Health Portfolio
      • Chapel Hill’s Achelios reports promising test results
    • 2014 News Releases >
      • Jazz Pharmaceuticals Announces Acquisition From Aerial Biopharma Of Rights To A Late Stage Investigational Compound
      • Aerial Hears a Cool Jazz $400M Wake-Up Call
    • 2013 News Releases >
      • TBJ 2013 Life Sciences Awards winners revealed
      • Aerial Biopharma Announces Closing of Second Tranche of Series A
    • 2012 News Releases >
      • Acorda Therapeutics Announces Completion of Neuronex, Inc. Acquisition
      • Aerial Biopbarma Receives FDA Orpban Drug Designation
      • A new migraine drug taken by skin? How Achelios could make it happen
      • Acorda 4Q profit climbs; company buying Neuronex
      • Addrenex Founders Sell Neuronex
    • 2011 News Releases >
      • Lookout Capital Announces Investment In EnviCor
  • Interests
  • Contact me